AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9643668
Drug: Tamsulosin (TAM)
DrugBank: Tamsulosin (DB00706)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tamsulosin (TAM) 0.4 mg once daily after breakfast for 15 days
Trial: 8196850
Drug: Fluoxetin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetin (20 mg/die) and cyclobenzaprine (10 mg/die)
Trial: 8196850
Drug: Cyclobenzaprine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclobenzaprine (10 mg/die)
Trial: 3286577
Drug: Oral acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral acyclovir (400 mg three times a day on Days -6 to +14 and 200 mg three times a day on Days +15 to +90 for adults; 500 mg/m2 per day divided into three doses on Days -6 to +14 and 250 mg/m2 per day divided into three doses on Days +15 to +90 for children)
Trial: 9593014
Drug: HDCV three-injection
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HDCV three-injection regimen
Trial: 9593014
Drug: PVRV three-injection
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PVRV three-injection regimen
Trial: 9593014
Drug: Booster injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Booster injection at 1 year
Trial: 19149880
Drug: Passive Physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Passive Physical Therapy (PPT)
Trial: 12065553
Drug: Maintenance therapy
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance therapy (MT) consisting of mercaptopurine and cytarabine for 18 months
Trial: 12548362
Drug: Apo‐TD (transdermal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apo‐TD (transdermal apomorphine)
Trial: 12548362
Drug: L‐dopa plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐dopa plus Apo‐TD
Trial: 8030657
Drug: Oral prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral prednisone (group 1)
Trial: 8030657
Drug: High-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intravenous gammaglobulin (group 2)
Trial: 8030657
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of both agents (group 3)
Trial: 31079356
Drug: Yimitasvir 400
RxNorm normalized name: Yimitasvir
DrugBank: Yimitasvir (DB18768)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yimitasvir 400 mg
Trial: 31079356
Drug: Yimitasvir 100
RxNorm normalized name: Yimitasvir
DrugBank: Yimitasvir (DB18768)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yimitasvir 100 mg once daily for 7 days
Trial: 31079356
Drug: Yimitasvir 200
RxNorm normalized name: Yimitasvir
DrugBank: Yimitasvir (DB18768)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yimitasvir 200 mg once daily for 7 days
Trial: 25223731
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg selisistat
Trial: 24235227
Drug: Vectormune FP
RxNorm normalized name: Coagulation Factor IX (Recombinant), Albumin Fusion Protein (rIX-FP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vectormune FP MG vaccination
Trial: 21621660
Drug: Passive Treatment
RxNorm normalized name: RESPIRATORY TUBE 22MM PASSIVE R#1147378
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Passive Treatment
Trial: 17033604
Drug: NaCl 0.9%
RxNorm normalized name: DEXTROSE 5%/NACL 0.9% INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaCl 0.9% 3x100 mL
Trial: 9234031
Drug: Ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic acid (AA) supplementation (1 g per day for two weeks)
Trial: 3941213
Drug: OKY‐046, 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OKY‐046, 400 mg/day orally
Trial: 30125761
Drug: docetaxel 75
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: docetaxel 75 mg/m2, doxorubicin 50 mg/m2 and cyclophosphamide 500 mg/m2 every 3 weeks (TAC)
Trial: 30125761
Drug: doxorubicin 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 every 2 weeks (ddAC)
Trial: 26649909
Drug: Adductor Canal
RxNorm normalized name: Canalevia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adductor Canal Block (ACB) with 30 mL ropivacaine 0.75% at t0 and 30 mL saline at t60
Trial: 25022831
Drug: Ambulatory treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambulatory treatment (12 days of hospital visits over 6 months)
Trial: 15867204
Drug: R-CHOP (rituximab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-CHOP (rituximab 375 mg/m² + CHOP)
Trial: 9705024
Drug: 5-HTP (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-HTP (750 mg/d)
Trial: 8539554
Drug: Lower antigen
RxNorm normalized name: TRICOPHYTON ANTIGEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower antigen content vaccine (10 micrograms pertussis toxoid and 5 micrograms filamentous hemagglutinin)
Trial: 11833825
Drug: Both vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both vaccine formulations
Trial: 2181857
Drug: Silicone-rubber balloon
RxNorm normalized name: CATHETER BALLOON SILICONE 18FR 5CC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silicone-rubber balloon inflated with 400 mL for 1 month
Trial: 18834910
Drug: Licensed ACWY
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Licensed ACWY polysaccharide vaccine
Trial: 7024020
Drug: Continuous subcutaneous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous subcutaneous insulin infusion (CSII) after 3 weeks of treatment
Trial: 7579030
Drug: Caffeine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (60 mg)
Trial: 25139268
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of propofol + meperidine
Trial: 25139268
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of midazolam + meperidine
Trial: 14981104
Drug: Bilateral prophylactic
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral prophylactic mastectomy with prior or concurrent bilateral prophylactic oophorectomy
Trial: 30064718
Drug: Guanfacine extended
RxNorm normalized name: Guanfacine Extended-Release Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guanfacine extended release (GXR) 1-7 mg/day; morning administration
Trial: 18373710
Drug: Efalizumab 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efalizumab 2 mg/kg weekly for 3 months
Trial: 18373710
Drug: Efalizumab (dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efalizumab (dosage not specified) during the optional transition period
Trial: 10823256
Drug: Adjusted dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjusted dose intravenous UFH
Trial: 10823256
Drug: Fixed dose
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed dose subcutaneous LMWH Certoparin
Trial: 1797193
Drug: 30 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/m2 epirubicin weekly
Trial: 1797193
Drug: 90 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 mg/m2 epirubicin every 3 weeks
Trial: 6344649
Drug: Oral ampicillin
RxNorm normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ampicillin for 24 hours preceding and 3 days following surgery
Trial: 329946
Drug: No prophylactic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No prophylactic treatment
Trial: 31982075
Drug: Eplerenone (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eplerenone (25 mg/day for 1 week, increasing to 50 mg/day for up to 12 months) plus usual care
Trial: 22946768
Drug: Weekly pursed-lips
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly pursed-lips breathing (PLB) reinforcement sessions via Skype for 4 weeks
Trial: 19341357
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of lecture and simulation
Trial: 17617281
Drug: Hydrocodone/acetaminophen (H/A)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocodone/acetaminophen (H/A) 5/500 mg
Trial: 11408793
Drug: DA antagonist
RxNorm normalized name: DAS-181
DrugBank: DAS-181 (DB15313)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DA antagonist (fluphenazine 2 mg)
Trial: 8291866
Drug: Adjuvant prophylactic
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant prophylactic instillation treatments (local cytostatics and immunoagents)
Trial: 16681880
Drug: Celecoxib 200
RxNorm normalized name: celecoxib 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib 200 mg/d
Trial: 19809337
Drug: Quetiapine (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine (up to 800 mg/day)
Trial: 8685930
Drug: Maprotiline (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maprotiline (150 mg/d)
Trial: 18853934
Drug: Zolpidem extended-release
RxNorm normalized name: zolpidem Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolpidem extended-release 12.5 mg
Trial: 9181646
Drug: Zidovudine 600
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zidovudine 600 mg/day
Trial: 9181646
Drug: Didanosine 400
RxNorm normalized name: didanosine 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Didanosine 400 mg/day
Trial: 30193294
Drug: Group-Administered Behavioral
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group-Administered Behavioral Treatment (GBT)
Trial: 15823767
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine plus metformin
Trial: 24614911
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine plus glimepiride
Trial: 24614911
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine plus glimepiride plus metformin
Trial: 10351191
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human insulin-like growth factor I (rhIGF-I) therapy
Trial: 1983500
Drug: Midazolam (0.2‐0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.2‐0.4 mg/kg/h)
Trial: 1983500
Drug: Clonidin (1‐2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidin (1‐2 mg/d)
Trial: 1983500
Drug: Alcohol substitution
RxNorm normalized name: hydroxypropyl cellulose, low substituted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol substitution (1‐2 g/kg/d)
Trial: 3544186
Drug: Atropine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine (1 mg)
Trial: 29080915
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg ranibizumab
Trial: 21684606
Drug: Sham/0.5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham/0.5 mg group
Trial: 10667640
Drug: MPFF 1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MPFF 1000 mg/day for 6 weeks
Trial: 10667640
Drug: MPFF 1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MPFF 1000 mg/day for 2 months
Trial: 10667640
Drug: MPFF 1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MPFF 1000 mg once daily or bid for 2 months
Trial: 1298597
Drug: Individualized administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individualized administration of gentamicin
Trial: 1298597
Drug: Conventional administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional administration of gentamicin
Trial: 15082469
Drug: Anakinra 100
RxNorm normalized name: ANAKINRA 100MG INJ,SYRINGE,1ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anakinra 100 mg/day
Trial: 17397098
Drug: Antipsychotic (AP)
RxNorm normalized name: AP-101
DrugBank: AP-101 (DB17947)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotic (AP) polypharmacy
Trial: 17397098
Drug: Typical AP
RxNorm normalized name: AP-101
DrugBank: AP-101 (DB17947)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Typical AP drugs
Trial: 17397098
Drug: Clozapine and
RxNorm normalized name: Clozapine
DrugBank: Clozapine (DB00363)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clozapine and atypical and oral AP
Trial: 16288613
Drug: 0.1 mg
RxNorm normalized name: biotin 0.1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg morphine (group BM0.1)
Trial: 17197846
Drug: ADVANCE (family-centered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADVANCE (family-centered behavioral preparation)
Trial: 7908164
Drug: Ibopamine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibopamine (100 mg, 3 times/day)
Trial: 19384186
Drug: Calcineurin inhibitor
RxNorm normalized name: Calcineurin inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcineurin inhibitor (CNI)
Trial: 29488482
Drug: Ursosan (UDCA)
RxNorm normalized name: UDCA
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursosan (UDCA) 15 mg/kg for 24 weeks
Trial: 2140095
Drug: Nisoldipine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nisoldipine (0.5 mg)
Trial: 24510176
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate nasal spray 200 μg once daily for 8 weeks
Trial: 24510176
Drug: Oral clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral clarithromycin 500 mg twice daily for 2 weeks, then 250 mg once daily for 6 weeks, plus mometasone furoate
Trial: 24510176
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (clarithromycin + mometasone)
Trial: 17917441
Drug: Multinational norfloxacin
RxNorm normalized name: Norfloxacin
DrugBank: Norfloxacin (DB01059)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multinational norfloxacin tablet (Noroxin)
Trial: 15842025
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care plus a systematic care management program including initial assessment, monthly telephone monitoring, feedback to treatment team, and structured group psychoeducational program provided by a nurse care manager.
Trial: 12197593
Drug: Esmolol group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmolol group (intravenous esmolol drip during CPB to maintain heart rate at 30‐50 beats/min)
Trial: 41546
Drug: Glutethimide 500
RxNorm normalized name: glutethimide 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glutethimide 500 mg
Trial: 16377449
Drug: Daily IVR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily IVR reporting with personal follow-up on noncompliant callers
Trial: 16377449
Drug: Daily IVR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily IVR reporting without follow-up
Trial: 14529670
Drug: Carboplatin (AUC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carboplatin (AUC 6), followed by paclitaxel (175 mg/m(2) over 3 h) (C-P)
Trial: 14529670
Drug: Paclitaxel (175
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel (175 mg/m(2) over 3 h), followed by carboplatin (AUC 6) (P-C)
Trial: 10923634
Drug: Glucose infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose infusion (6 mg/kg over 1 min every 10 min)
Trial: 8753109
Drug: G-CSF (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF (50 microns/m2, subcutaneously) administered when leukocyte count is ≤ 1000/mm3
Trial: 8753109
Drug: G-CSF (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF (50 microns/m2, subcutaneously) administered when leukocyte count is between 1000/mm3 and 2000/mm3
Trial: 21307009
Drug: Dexmedetomidine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (1 µg kg(‐1) i.v. over 20 min followed by 0.7 µg kg(‐1) h(‐1) infusion for 190 min)
Trial: 21307009
Drug: Morphine hydrochloride
RxNorm normalized name: Morphine hydrochloride
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine hydrochloride (0.10 mg kg(‐1) i.v. over 20 min)
Trial: 28030444
Drug: Sugammadex (2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugammadex (2.0 mg/kg)
Trial: 3516510
Drug: Diphenhydramine 100
RxNorm normalized name: acetaminophen-diphenhydramine 1000 mg-50 mg/30 mL oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diphenhydramine 100 mg
Trial: 11314681
Drug: Lorazepam 1.5
RxNorm normalized name: lorazepam 1.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam 1.5 mg
Trial: 16401664
Drug: Diphenhydramine (50,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diphenhydramine (50, 75, and 100 mg)
Trial: 10757250
Drug: Lorazepam 0.5
RxNorm normalized name: lorazepam 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam 0.5 mg
Trial: 9924298
Drug: 99mTc‐carbon gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 99mTc‐carbon gel
Trial: 7752839
Drug: Soft gelatin
RxNorm normalized name: Norvir Soft Gelatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soft gelatin capsule containing 100 mg of CoQ with 400 mg of soy bean oil (Bioquinon)
Trial: 7752839
Drug: Soft gelatin
RxNorm normalized name: Norvir Soft Gelatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soft gelatin capsule containing 100 mg of CoQ with 20 mg of polysorbate 80 and 380 mg of soy bean oil
Trial: 31161926
Drug: Audiobook (AB)
RxNorm normalized name: Crotalidae immune F(ab')2 Injection [Anavip]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Audiobook (AB) placebo treatment
Trial: 24841502
Drug: Ultrasound-assisted epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-assisted epidural steroid injections
Trial: 24841502
Drug: Fluoroscopic-guided epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoroscopic-guided epidural steroid injections
Trial: 16579998
Drug: Measurements of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Measurements of serum insulin, leptin, sOB-R at fasting and during a standard oral glucose tolerance test (OGTT)
Trial: 12061352
Drug: Ibuprofen-arginine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen-arginine (1 drop/kg: 6.67 mg/kg)
Trial: 12061352
Drug: Paracetamol (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol (4 drops/kg: 10.65 mg/kg)
Trial: 9207871
Drug: Ibuprofen-arginine
RxNorm normalized name: Arginine
DrugBank: Arginine (DB00125)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen-arginine
Trial: 7771617
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg LMWH (enoxaparin) once daily
Trial: 2313607
Drug: Non-insulin-dependent diabetes
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-insulin-dependent diabetes (diet, tablet, or ultralente insulin therapy)
Trial: 6342565
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of amitriptyline hydrochloride, up to 150 mg/day, and tranylcypromine, up to 20 mg/day
Trial: 16329018
Drug: Meperidine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meperidine 0.5 mg/kg intravenously (group 1)
Trial: 15734603
Drug: Tibolone 5.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tibolone 5.0 mg
Trial: 15734603
Drug: Tibolone 0.625
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tibolone 0.625 mg
Trial: 15734603
Drug: Tibolone (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tibolone (all doses)
Trial: 7768667
Drug: Adrenocorticotropic hormone
RxNorm normalized name: Adrenocorticotropic hormone
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adrenocorticotropic hormone (ACTH) administration
Trial: 2179769
Drug: Ticlopidine (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticlopidine (500 mg per diem for 15 days)
Trial: 380742
Drug: Low-dose subcutaneous
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose subcutaneous heparin (5000 IU eight-hourly)
Trial: 31187264
Drug: High flow
RxNorm normalized name: Blood Set High Flow
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High flow nasal cannula at 8 L/min
Trial: 31187264
Drug: High flow
RxNorm normalized name: Blood Set High Flow
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High flow nasal cannula (4, 6, and 8 L/min)
Trial: 22341702
Drug: Everolimus (C(0):
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus (C(0): 50 to 90 ng/ml)